Diversify Wealth Management LLC Raises Holdings in Gilead Sciences, Inc. $GILD

Diversify Wealth Management LLC increased its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 87.4% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 10,875 shares of the biopharmaceutical company’s stock after acquiring an additional 5,072 shares during the quarter. Diversify Wealth Management LLC’s holdings in Gilead Sciences were worth $1,401,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also bought and sold shares of the stock. Strategic Investment Solutions Inc. IL bought a new position in shares of Gilead Sciences in the fourth quarter worth approximately $25,000. Vermillion & White Wealth Management Group LLC increased its stake in shares of Gilead Sciences by 71.4% in the fourth quarter. Vermillion & White Wealth Management Group LLC now owns 204 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 85 shares during the period. Quattro Advisors LLC bought a new stake in Gilead Sciences during the 4th quarter valued at $26,000. Wealth Preservation Advisors LLC raised its holdings in Gilead Sciences by 60.0% during the 4th quarter. Wealth Preservation Advisors LLC now owns 216 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 81 shares during the last quarter. Finally, Ares Financial Consulting LLC purchased a new stake in Gilead Sciences during the 4th quarter valued at $28,000. 83.67% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on GILD. Royal Bank Of Canada cut their price target on shares of Gilead Sciences from $122.00 to $120.00 and set a “sector perform” rating on the stock in a report on Tuesday, July 7th. The Goldman Sachs Group upped their price objective on shares of Gilead Sciences from $125.00 to $130.00 and gave the company a “neutral” rating in a research note on Friday, April 17th. Leerink Partners dropped their target price on shares of Gilead Sciences from $148.00 to $146.00 in a report on Friday, May 8th. Weiss Ratings cut Gilead Sciences from a “buy (b)” rating to a “buy (b-)” rating in a research note on Thursday, May 28th. Finally, Rothschild & Co Redburn reduced their price target on Gilead Sciences from $170.00 to $167.00 in a report on Monday, May 11th. Twenty-six analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $159.04.

Insiders Place Their Bets

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 3,000 shares of Gilead Sciences stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $125.40, for a total transaction of $376,200.00. Following the sale, the chief financial officer directly owned 171,646 shares of the company’s stock, valued at approximately $21,524,408.40. The trade was a 1.72% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O’day sold 15,000 shares of the company’s stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $126.29, for a total value of $1,894,350.00. Following the transaction, the chief executive officer owned 607,133 shares in the company, valued at $76,674,826.57. This trade represents a 2.41% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 77,000 shares of company stock worth $9,978,740 over the last three months. Company insiders own 0.30% of the company’s stock.

Gilead Sciences Stock Down 1.0%

Shares of Gilead Sciences stock opened at $130.04 on Wednesday. The company has a current ratio of 1.97, a quick ratio of 1.77 and a debt-to-equity ratio of 0.89. The company’s fifty day simple moving average is $129.72 and its two-hundred day simple moving average is $135.11. The company has a market cap of $161.45 billion, a P/E ratio of 17.72 and a beta of 0.32. Gilead Sciences, Inc. has a 12-month low of $107.75 and a 12-month high of $157.29.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 EPS for the quarter, topping the consensus estimate of $1.91 by $0.12. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. The firm had revenue of $6.96 billion during the quarter, compared to analysts’ expectations of $6.91 billion. During the same period last year, the company posted $1.81 EPS. The company’s quarterly revenue was up 4.4% compared to the same quarter last year. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. Research analysts anticipate that Gilead Sciences, Inc. will post -0.79 EPS for the current year.

Gilead Sciences Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Monday, June 29th. Investors of record on Monday, June 15th were paid a $0.82 dividend. This represents a $3.28 dividend on an annualized basis and a yield of 2.5%. The ex-dividend date of this dividend was Monday, June 15th. Gilead Sciences’s dividend payout ratio is presently 44.69%.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.